Prediabtes isn’t “ Almost Diabetes” . This episode explains how type 2 diabetes often begins years before diagnosis as prediabetes — a compensatory metabolic state where insulin resistance, pancreatic stress, liver overproduction of glucose, and visceral fat-driven inflammation quietly disrupt glucose control.

You’ll learn the diagnostic thresholds (A1c 5.7–6.4%, fasting glucose 100–125 mg/dL, 2‑hour OGTT 140–199 mg/dL), why different tests can identify different people, who should be tested, and which clinicians to involve (PCP, endocrinologist, dietitian, diabetes prevention programs).

The episode emphasizes prevention: lifestyle-based diabetes prevention programs can reduce progression, metformin is not automatic, and early action can change your metabolic trajectory — protecting overall health and reducing future foot and limb complications.

This episode explains what "stump shrinkage" really means—residual limb volume changes, edema, tissue remodeling, and how different amputation levels affect function and prosthetic fitting.

It outlines practical management steps: compression and dressing strategies, wound and vascular monitoring, prosthetic planning, physical therapy, and the extra vigilance required for people with diabetes to protect the remaining limb and restore mobility.

This episode explores why some diabetic foot ulcers remain inflamed yet fail to clear microbes, distinguishing contamination, colonization, local infection, and clinical infection. It explains how immune dysregulation, neutrophil extracellular traps (NETs), macrophage dysfunction, biofilm, ischemia, hypoxia, neuropathy, and necrotic tissue create an ecosystem that prevents healing.

The episode emphasizes that antibiotics alone are not enough: effective care requires assessing perfusion, offloading, debridement, glycemic and systemic management, targeted antimicrobials when indicated, and ongoing surveillance to change the wound trajectory.

Dr. G discusses realistic expectations for diabetic foot ulcer healing, explaining the medical factors that affect recovery—blood flow, infection control, offloading, nutrition, and time—and why instant results are unlikely.

She contrasts routine wound healing with the emotional and practical challenges of limb salvage, emphasizes tracking progress with measurements and photos, celebrates small victories, and urges patients to seek mental-health support when needed.

In this episode Dr. G explains why tissue adhesives like cyanoacrylates (e.g., Dermabond) work well for clean, superficial, low‑tension wounds but are inappropriate for diabetic foot ulcers. Diabetic ulcers involve neuropathy, poor perfusion, infection risk, dead space, undermining and impaired healing biology that glues cannot fix.

Key takeaways: adhesives only bond superficial skin edges and do not treat infection, necrosis, ischemia or structural problems; using glue can trap drainage and mask deeper issues; tissue glue may last days but is not a cure for complex diabetic wounds.

Dr. G explains what dead space is — a residual tissue cavity after tissue loss or separation in the diabetic foot — why it matters, and how it differs from abscesses, undermining, and tunneling.

He outlines how to recognize dead space (probing, persistent drainage, imaging), its impact on healing, and practical management strategies including debridement, drainage, infection control, offloading, and prevention.

Dr. G explains transepidermal water loss (TEWL) and why a clinically closed diabetic foot ulcer can still have a compromised skin barrier. He outlines how TEWL reflects epidermal function, how diabetes and neuropathy impair skin recovery, and why “functional closure” differs from simple epithelialization.

A multicenter study found higher TEWL at recently closed ulcer sites was linked to increased and earlier recurrence, suggesting TEWL could help guide extended offloading, closer follow‑up, and targeted care to reduce re‑ulceration risk.

Dr. G explores how the tiny nematode C. elegans helps researchers study key processes related to diabetic foot ulcers, including wound detection, calcium signaling, cytoskeletal remodeling, mitochondrial reactive oxygen species, innate immune responses, and bacterial virulence.

While the worm cannot reproduce the full complexity of human diabetic foot disease, its transparency and genetic tractability make it a powerful early-stage model to identify pathways and test hypotheses that could inform future treatments.

This episode explains Erysipelothrix rhusiopathiae, an animal-associated bacterium that can enter through minor skin breaks—often from fish, meat, or livestock exposure—and cause a localized lesion called erysipeloid.

It highlights diagnostic traps in diabetic foot care, the importance of occupational history (remember FISH: Fish exposure, Inoculation, Slowly expanding lesion, Heart involvement), the organism's intrinsic resistance to vancomycin, and the potential for systemic disease including endocarditis.

Dr. G explains why informed consent in diabetic foot care is more than paperwork: it’s a time-sensitive conversation about capacity, risks, alternatives, and what happens if treatment is delayed.

The episode covers capacity versus competency, surrogate and physician consent in emergencies, the emotional weight of amputation decisions, and a four-phase consent model to help patients understand trajectories and make informed choices.